<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653119</url>
  </required_header>
  <id_info>
    <org_study_id>PUCRP-004</org_study_id>
    <nct_id>NCT01653119</nct_id>
  </id_info>
  <brief_title>Peking and Rotterdam on Mission to Reduce Coronary Artery Disease</brief_title>
  <acronym>PROMISS</acronym>
  <official_title>Peking and Rotterdam on Mission to Reduce Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the effect of 20mg high loading dose of rosuvastatin
      on recurrent events in patients with established DM who is admitted for an ACS.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of cardiovascular mortality or a clinical diagnosis of a non-fatal ACS</measure>
    <time_frame>during 12 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A composite of cardiovascular mortality or a clinical diagnosis of a non-fatal ACS</measure>
    <time_frame>during 30 days follow-up</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The proportion of any AST or ALT &gt;3 x ULN or CK &gt;5 x ULN</measure>
    <time_frame>during the 1-year follow up period</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>High loading dose of rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rosuvastatin 20mg/d×1w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine rosuvastatin therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rosuvastatin 10mg/d×1w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.</description>
    <arm_group_label>High loading dose of rosuvastatin</arm_group_label>
    <arm_group_label>Routine rosuvastatin therapy</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Men or women ≥40 years of age admitted with a clinical diagnosis of ACS. The
             diagnosis should be based on the combination of typical ischemic chest complaints and
             objective evidence of myocardial ischemia or myocardial necrosis as demonstrated by
             the electrocardiogram (ECG) or elevated cardiac markers, as follows:

          -  Typical ischemic chest pain, lasting 10 minutes or more, within the preceding 24
             hours, AND either

          -  ECG changes indicative of myocardial ischemia within 24 hours after the onset of chest
             pain (ECG showing persistent or non-persistent ST-segment elevation &gt;1.0 mm in two or
             more contiguous leads or dynamic ST-segment depression &gt;1.0 mm in two or more
             contiguous leads) or

          -  Elevated biomarkers of myocardial necrosis within 24 hours after the onset of chest
             pain (i.e. CK-MB &gt;1 times the upper limit of normal of the local laboratory, or
             Troponin-T &gt;0.1 ng/ml.

               -  A diagnosis of DM type II prior to the index ACS

               -  Written informed consent

        Exclusion Criteria:

          -  • Myocardial ischemia precipitated by a condition other than atherosclerotic coronary
             artery disease (e.g. arrhythmia, severe anemia, hypoxia, thyrotoxicosis, cocaine,
             severe valvular disease, hypotension).

               -  Severely-impaired left ventricular function (ejection fraction &lt;30%) or end-stage
                  congestive heart failure NYHA-class III or IV (in order to avoid
                  lost-to-follow-up due to non-acute coronary syndrome events).

               -  Severe chronic kidney disease with measured or calculated glomerular filtration
                  rate (Cockgroft-Gault or MDRD4 (Modification of Diet in Renal Disease) formula)
                  of &lt;30 ml/min/1.73m2, or renal dialysis.

               -  Co-existent condition associated with a life-expectancy &lt;12 months, or otherwise
                  unlikely to appear at all scheduled follow-up visits.

               -  Known serious or hypersensitivity reactions to HMG-CoA reductase inhibitors.

               -  Triglyceride (TG) level ≥500 mg/dL (5.65 mmol/L) at screening, because patients
                  with very high triglyceride levels warrant treatment with agents that may
                  increase the risk of side effects associated with statin drugs.

               -  Active liver disease or hepatic dysfunction, as determined by alanine
                  aminotransferase (ALT [SGPT]) &gt;3 x ULN or bilirubin levels &gt;1.5 x ULN at
                  screening.

               -  Myopathy.

               -  Not using effective contraceptive methods.

               -  Participation in any investigational drug study less than 30 days prior to
                  enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Gao, Master</last_name>
    <phone>+8613901366179</phone>
    <email>dr_gaowei@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Zhao</last_name>
    <phone>+8618600017812</phone>
    <email>beate_vv@bjmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Gao, Master</last_name>
      <phone>+8613901366179</phone>
      <email>dr_gaowei@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Wei Zhao, Doctor</last_name>
      <phone>+8618600017812</phone>
      <email>beate_vv@bjmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2012</study_first_posted>
  <last_update_submitted>July 26, 2012</last_update_submitted>
  <last_update_submitted_qc>July 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Wei Gao</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Statins</keyword>
  <keyword>High loading dose</keyword>
  <keyword>Recurrent events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

